Teresa Austin Karre, MD, FCAP, member of the CAP Microbiology Committee, discusses a recent CDC report about drug-resistant infections. It’s important to distinguish between technologies used for screening asymptomatic populations and those used to confirm carbapenemase production in clinical isolates from infection sites. These represent two distinct pathways to identifying CPOs.
For the full article click here: Inside the CDC’s Warning on Drug-Resistant Infections